On May 19, 2025, SEUM IP’s client ImmuneOncia made a successful debut on the KOSDAQ, closing at twice its initial public offering (IPO) price on its first day of trading.

ImmuneOncia is a biotech company developing innovative cancer therapies using immune cells, with a focus on antibody therapeutics targeting T cells and macrophages. Its key pipeline assets include IMC-001 (Anti-PD-L1) and IMC-002 (Anti-CD47), which are currently undergoing both domestic and global clinical trials and technology transfer efforts.

Notably, IMC-002 was out-licensed to China’s 3D Medicines in 2021 in a deal valued at approximately USD 470.5 million, demonstrating its global potential. IMC-001 is actively under development with a target for global out-licensing by 2027 and domestic commercialization by 2029.

ImmuneOncia achieved a strong performance during the IPO process, recording an institutional demand ratio of 897.45:1 and a retail subscription ratio of 913:1. On its first trading day, the stock closed at KRW 7,500, a 108% increase from the IPO price of KRW 3,600.

SEUM IP has been providing ImmuneOncia with comprehensive IP support — from initial patent-strategy development and IP-portfolio building during the clinical-trial stage to legal and strategic guidance throughout listing preparation. SEUM IP remains committed to delivering expert IP advisory services that enhance technological competitiveness for biopharmaceutical clients.